Institutional Insights on CDK4/6 Inhibitor Adherence in Breast Cancer

Opinion
Video

Aimee Keegan, PharmD, BCOP, discusses how her institution optimizes patient adherence to CDK4/6 inhibitors, highlighting resources including their in-house specialty pharmacy.

This is a synopsis of a Peer Exchange series featuring Aimee Keegan, PharmD, BCOP, of City of Hope.

Aimee Keegan, PharmD, BCOP, discusses the various resources available at City of Hope to help ensure patient adherence to medications with significant toxicities, such as CDK4/6 inhibitors. One of these resources is an online portal that allows patients to communicate with their care team at any time, particularly regarding side effects or medication issues, instead of waiting for their next scheduled appointment.

Dr. Keegan also mentions a 24/7 triage line staffed by nurses, which patients can call for urgent side effects or issues, receiving immediate advice or guidance from the care team. Additionally, City of Hope has established its own specialty pharmacy, which has greatly improved patient adherence. The specialty pharmacists and technicians call every patient who fills their specialty medications with them about a week before their refill is due, not only to arrange medication delivery but also to interview each patient.

During these calls, the specialty pharmacy team asks patients about missed doses, new medications, changes in medical conditions, and herbal supplementation. If any side effects are reported, the pharmacist can provide counseling and supportive care options to help the patient overcome the issue and continue therapy. If missed medications or intolerable side effects are reported, the specialty pharmacy team sends a message to the clinic's care team to address the issue promptly.

Furthermore, the specialty pharmacy assists patients with financial assistance, such as copay cards for commercial patients, foundation assistance, and City of Hope's patient assistance program, which offers free medication to patients who cannot afford it. Dr. Keegan emphasizes that providing access to medications and supporting side effect management through these resources has significantly improved patient adherence to CDK4/6 inhibitors.

*Video synopsis is AI-generated and reviewed by Pharmacy Times editorial staff.

Related Videos
Video 10 - "Valuable Metrics and Improving Adherence in Patients With ASCVD"
Video 9 - "The Role of Pharmacists in Treating Very High-Risk ASCVD"
Video 6 - "evaluating CDK4/6 inhibitor safety profiles"
Video 5 - "CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC"
Video 8 - "Challenges of Concurrent Administration: RSV and Other Vaccines "
Video 7 - "Raising RSV Awareness Among High-Risk Patient Populations "
A panel of 5 experts on ASCVD
A panel of 5 experts on ASCVD
Video 4 - "Applying NCCN Guidelines in the Treatment of mBC"
© 2024 MJH Life Sciences

All rights reserved.